Impact Of Rising Healthcare Spending On Meningococcal Vaccines Is Supporting Development Across The Meningococcal Vaccines Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Meningococcal Vaccines Market Over The Forecast Period?

The market size for meningococcal vaccines has experienced significant expansion in recent years. This market is anticipated to expand from $4.26 billion in 2025 to $4.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. The historical growth in this sector is attributable to several factors, including the introduction of meningococcal conjugate vaccines, a rising incidence of meningitis outbreaks, government immunization campaigns, growing pediatric vaccination coverage, and increased public health funding.

The meningococcal vaccines market is anticipated to experience substantial growth over the coming years. Its valuation is projected to reach $6.58 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This expansion during the forecast period is driven by factors such as progress in vaccine technology, the widening scope of global immunization efforts, heightened understanding of meningococcal disease, strategic alliances, and increased vaccination drives targeting adolescents and young adults. Key developments expected during this period involve the broadening of pediatric vaccination programs, the creation of comprehensive broad-spectrum meningococcal vaccines, strengthened government-led immunization campaigns, growing recognition of the importance of preventing meningococcal disease, and an uptick in vaccination initiatives within schools and colleges.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Market Drivers Are Helping Shape The Meningococcal Vaccines Market Expansion?

Rising healthcare expenditure is projected to boost the expansion of the meningococcal vaccine market. Healthcare encompasses establishments such as residential care facilities, nursing homes, and intermediate care facilities catering to individuals with mental illnesses or mental retardation. The considerable cost of newer vaccine generations, when compared to older ones, has become a central point in debates regarding if their advantages warrant their price tags. Evaluating the full societal and economic advantages of vaccination is emerging as an increasingly significant research focus within the literature concerning vaccine valuation. For example, data from an April 2025 article by the American Medical Association, a U.S.-based professional body and lobbying organization for doctors and medical students, showed that U.S. health spending grew by 7.5% in 2023, reaching $4.9 trillion or $14,570 per person. This particular growth rate substantially surpassed the 4.6% increase observed in 2022. Consequently, the rise in healthcare spending is propelling the expansion of the meningococcal vaccine market.

How Is The Meningococcal Vaccines Market Distributed Across Key Segments?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Which Trends Are Contributing To Changes In The Meningococcal Vaccines Market?

Major companies active in the meningococcal vaccines market are developing new vaccines for preventing serogroups, intending to boost their market profitability. Meningococcal vaccines are designed as preventive measures to safeguard individuals from infections caused by specific serogroups of the Neisseria meningitidis bacteria. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company, obtained approval from the FDA for its vaccine, PENBRAYA. PENBRAYA, featuring extensive serogroup coverage, stands as the most comprehensive U.S.-approved meningococcal vaccine, protecting against groups A, B, C, W, and Y. The FDA’s approval is founded on robust Phase 2 and 3 trial data, confirming non-inferior immunogenicity to Trumenba + Menveo across all serogroups, complemented by favorable safety. Pfizer’s announcement in September 2022 had previously unveiled positive results from a Phase 3 trial, comparing PENBRAYA to existing licensed meningococcal vaccines regarding its safety, tolerability, and immunogenicity.

Which Companies Form The Competitive Landscape Of The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Access The Complete Meningococcal Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Which Region Leads The Meningococcal Vaccines Market By Size?

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Meningococcal Vaccines Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2026, By The Business Research Company

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795